AbbVie Reports Phase 3 INSPIRE Results for Skyrizi in Ulcerative Colitis

AbbVie today announced results from the Phase 3 INSPIRE trial evaluating Skyrizi (risankizumab) in patients with moderately to severely active ulcerative colitis. The trial met its primary endpoints, demonstrating significantly higher rates of clinical remission and endoscopic improvement compared to placebo at week 12 and week 52. These results led to FDA approval of Skyrizi for ulcerative colitis.